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At the same time, verbal cognitive function was assessed with the California Verbal 
Learning Test (CVLT) and the Verbal Fluency test (VF). The Clinical Global Impres-
sion-Severity (CGI-S) was assessed as well at the same visits. Statistical analysis was 
done using SAS 9.2 with the PROC MIXED module for mixed effects repeated mea-
sures analysis. RESULTS: A mixed models analyses on the QLESQ scores showed 
signiﬁ cant effects for CGI-S in all subscores but “ school “ (p = 0,1485) and for the 
verbal cognitive measures only in subscores “leisure “ for CVLT-LTFR (p = 0,0002). 
CONCLUSIONS: The observed difference over time in QLESQ values is dependent 
on the CGI-S score which contributes mostly to the prediction of the QLESQ outcome. 
Verbal cognitive outcome was not predictive . These ﬁ ndings are not in agreement 
with other publications reporting an independent contribution of both measures on 
quality of life. As the study was open-label, interpretation of the results should be 
approached with some caution.
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OBJECTIVES: The QUALITY study evaluated Quality-of-Life in schizophrenic 
patients treated with atypical antipsychotics (AAPs) in the ambulatory setting. 
METHODS: Patients (18–65 years-old) diagnosed with schizophrenia and had started 
treatment with one AAP before visit-1 (minimum: 4-weeks, maximum: 8-weeks) were 
enrolled into this Belgian study. At visit-1 patients’ demographics and medical history 
were recorded with follow-up visits after 3-, 6- and 9-months. At each visit, patients 
completed the Subjective Well-being under Neuropletic treatment short form (SWN-
K), while investigators assessed the Positive and Negative Symptom Scale (PANSS-8) 
and the Global Assessment of Functioning (GAF). RESULTS: A total of 121 patients 
(mean age 36.7 ± 10.8, 75.2% male) were enrolled with the main AAP treatments 
risperidone (31.4%), apripirazole (23.1%), quetiapine (20.7%). At baseline, the asso-
ciations between the SWN-K subscales and age, gender, positive/negative PANSS-
scores, Schizophrenia-subtype or treatment-subgroups were small. Mental-functioning 
and physical-functioning subscales were signiﬁ cantly correlated with negative PANSS-
scores, as was the emotional-regulation subscale with gender. The majority of changes 
from baseline in the SWN-K subscale scores were between −0.5 and +0.5 (range: −1.8 
to 1.6). Most mean changes were positive, suggesting that patients felt better compared 
to baseline. PANSS-8-score changes were slightly negative, suggesting decreases in 
symptom severity. 57.5% of patients showed symptom remission (PANSS-8-score ≤ 
3 after 6 months-of-treatment).GAF scores increased (study end: 8.2 ± 16.0) indicating 
improvement in the patient’s global functioning. By the study end, the number of 
hospitalizations and addictive substance use had decreased. Patients with more severe 
negative symptoms considered their mental- and physical-functioning better and men 
were more satisﬁ ed than women with their emotional-regulation. Few patients had 
sufﬁ cient disease insight; most patients had a vague notion or did not see that they 
were ill. CONCLUSIONS: The patients’ well-being seemed to improve slightly during 
the study without differences between the treatments. Patients having more severe 
negative symptoms considered their mental and physical functioning better at the 
study end.
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OBJECTIVES: Mood disorders are generally associated with a high level of productiv-
ity loss and a substantial economic burden. The aim of this study was to measure the 
impact of mood disorders on productivity in terms of absence from work, at-work 
productivity loss, and job performance among patients in the The Netherlands. 
METHODS: Patients meeting DSM-IV criteria for depressive disorder, dysthymic 
disorder, panic disorder (with or without agoraphobia), social phobia and generalised 
anxiety disorder were included from a large naturalistic trial in 7 Dutch mental health 
care centres. The short form of the Health and Labour Questionnaire (SF-HLQ) was 
used to assess absenteeism (days absent from work), presenteeism (at-work productiv-
ity loss) and job performance (on a 3-point scale ranging from ‘not impeded’ to ‘very 
much impeded’). ANOVA analyses and t-tests were performed to explore differences 
between socio-demographic groups. RESULTS: Of the total 702 patients, two thirds 
were in paid employment. Over 3 months, 55% reported long-term absenteeism (>2 
weeks), with a mean of 73 work days lost per patient, and 13% patients reported a 
shorter-term absenteeism (<2 weeks), with a mean of 33 work days lost per patient. 
Women were absent from work for a longer (99 days) than men (46 days) (P < 0.005). 
Presenteeism accounted for a 12% productivity loss in terms of working time lost. 
The number of days at work while impeded by health problems was numerically 
higher in men than in women (7.4 vs. 5.6, p > 0.05). Overall, 31% of the patients 
had difﬁ culties in job performance when at work. CONCLUSIONS: Mood disorders 
are associated with impairment of patients’ productivity in terms of absence from 
work, presenteeism and difﬁ culties in job performance The study demonstrated a 
tendency towards lower absenteeism and higher presenteeism in men compared to 
women. 
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OBJECTIVES: The objective of this study is to analyze antidepressants and anxiolytics 
drugs usage (ATC subgroups: N06A and N05B) in two mid European, neighbouring 
countries, Croatia and Slovenia, for the 9-year period, from 2000 to 2008. Further, 
the aim was to identify the generic drugs usage in each country, the price for DDD 
for original and generic drugs, and to identify the most prescribed drugs in each drug 
group. METHODS: The data have been obtained from the International Medical 
Statistics database for Croatia and Slovenia. Drugs usage is presented in deﬁ ned daily 
doses per 1000 inhabitants per day (DDD/1000) according to the WHO Methodology. 
Financial expenditure data are presented in Euros. An average cost per DDD was 
calculated for each drug group. RESULTS: In 2008, the total usage of antidepressants 
was higher in Slovenia (42.7 DDD/1000 inhabitants/day) than in Croatia (22 
DDD/1000 inhabitants/day), and it increased in both countries during the investigated 
period. The total usage of anxiolytics is more than 3 times higher in Croatia (67.4 
DDD/1000 inhabitants/day) than in Slovenia (22.2 DDD/1000/inhabitants/day). The 
total usage of anxiolytics decreased in Slovenia in 2008 in comparison with prescrip-
tions in 2000, while it increased in Croatia for 44.3% during the same period. The 
rate of generic prescriptions among antidepressants during the investigated period was 
higher in Croatia, i.e. in Croatia 73.6% of all prescribed antidepressants were generics 
in 2008, while in Slovenia 33.5%. CONCLUSIONS: Drugs prescription patterns are 
different comparing Croatia and Slovenia. a possible reason for relatively higher usage 
of anxiolytics and lower usage of antidepressants in Croatia could be depression 
treatment with anxiolytics. This indicates the need for a more thorough analysis and 
the introduction of national drugs guidelines for rational prescribing, monitoring and 
evaluation especially anxiolytics. Although the generic drugs usage in the mentioned 
groups is relatively high, it should be further supported and promoted.
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ANTIPSYCHOTIC PRESCRIBING TO THE ELDERLY: A TWO-YEAR 
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OBJECTIVES: Antipsychotic medicines are commonly prescribed to elderly patients. 
These patients are at an increased risk of adverse drug events because of age-related 
pharmacodynamic and pharmacokinetic changes. The primary aim of the study was 
to determine antipsychotic prescribing patterns and cost to patients aged 60 years and 
older in a private health care sector primary care patient population in 2008 and 2009. 
METHODS: A retrospective, exposure-cohort drug utilization study was conducted 
on prescription data of a pharmacy group in South Africa for 2008 and 2009. No 
diagnoses were available. All records for antipsychotics (MIMS category 1.5) for 
patients 60 years and older were extracted for analysis. RESULTS: A total of 1 800 
patients in 2008 and 3 086 patients in 2009 received 7 877 and 14 538 antipsychotic 
products at a sales value of R2 785 896 and R4 928 127, respectively. The average cost 
per antipsychotic product was R353.67 in 2008 and R338.98 in 2009. Most patients 
were female (61.78% in 2008 and 57.87% in 2009). Tablets were the preferred dosage 
form. Risperidone (37.55% in 2008, and 38.20% in 2009), quetiapine (27.56% and 
28.88%) and olanzapine (10.91% and 10.24%) together accounted for more than 
75% of antipsychotics prescribed to the elderly. a high percentage of atypical antipsy-
chotics (84.23% in 2008 and 85.14% in 2009) were prescribed. Differences were 
observed between 2008 and 2009 with respect to the prescribing frequency of the 
atypical antipsychotics (chi2 = 32.624; d.f. = 6; p < 0.0001). CONCLUSIONS: Pre-
scribing patterns were relatively similar in both years. The dosages and duration of 
treatment of antipsychotics should be investigated in relation to the diagnoses for 
which they are prescribed. It is recommended that diagnoses be included in databases 
and also that qualitative studies be conducted to determine possible side effects expe-
rienced by patients.
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OBJECTIVES: England has 152 Primary Care Trust (PCT) each having its own 
characteristics, and prescription patterns. As a consequence, PCT formulary lists 
differ, creating an additional hurdle for patient access to innovative medicines, often 
referred to as the post-code lottery. The objective of this study was to segment these 
PCTs in groups with homogeneous attitudes towards patient access for innovative 
drugs in Mental Health (MH) using a clustering analysis. METHODS: We collected 
all available information about the PCTs through public sources and the OneKey + 
database. We identiﬁ ed 62 variables per PCT and classiﬁ ed them in 5 groups: proﬁ le 
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of population, economic & ﬁ nancial information, organization, prescription pattern 
and patient management. We ﬁ rst ran a principal component analysis on quantitative 
variables and then a multiple correspondence analysis on qualitative variables, in order 
to get individuals coordinates of PCTs on several axes on which they were projected. 
We then merged the results, and ran an analysis to create PCTs clusters. RESULTS: 
We identiﬁ ed 5 clusters of PCTs with differentiated, homogeneous attitude towards 
innovative drugs. Cluster 1 focused on MH disorders with GP-level decision-making, 
cluster 2 focused on MH disorders and contained high-prescribing physicians, cluster 
3 had low recognition of MH disorders, cluster 4 had low recognition but offered a 
high level of care while cluster 5 was focused on cost containment. The clusters also 
varied in population size from 1.2 M to 23.9 M. CONCLUSIONS: As this work was 
rather innovative it was validated by local pharmaceutical sales and marketing orga-
nization. The cluster approach proposed was endorsed by account managers’ prag-
matic experience in the ﬁ eld and correlated well with their experience of obtaining 
access for their innovative MH drugs. This study helped to improve our understanding 
of the UK landscape in patient access for innovative drugs in MH.
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OBJECTIVES: Attention-Deﬁ cit/Hyperactivity Disorder (ADHD) is a neurobehavioral 
developmental disorder, that is characterized by hyperactivity and impulse control 
disorder. In Germany pharmaceutical therapy is approved for children and adolescents 
solely. Therefore, treating adult patients with ADHD complies with off-label use of 
stimulants. Aim of this Health Technology Assessment is to examine the clinical 
effectiveness, cost-effectiveness, ethical-social and legal aspects of pharmacotherapy 
(stimulants, antidepressants, norepinephrine reputake inhibitors) of adult ADHD 
patients. METHODS: A systematic literature research is conducted in relevant elec-
tronic literature databases. Studies matching the ex ante deﬁ ned inclusion criteria are 
assessed systematically and qualitatively according to methodical standards by two 
reviewers. Due to heterogeneity of included studies no meta-analysis is performed. 
RESULTS: Nine randomised controlled trials (RCT), ﬁ ve systematic reviews, three 
economic and two studies concerning legal aspects are included. All RCT show 
improvement regarding ADHD symptoms (hyperactivity, impulsivity). Response rates 
vary between 7 % and 42 % in the control group and 17 % to 59,6 % in the inter-
vention group. The studies use primarily investigator and self-rated questionnaires 
such as the ADHD Rating Scale, the Conners Scales and the Clinical Global Impression 
as outcome parameters for the core symptoms of ADHD. Some studies show a larger 
improvement of the ADHD symptoms by a ﬂ exible dose approach. The systematic 
reviews demonstrate statistically signiﬁ cant improvement in symptoms of ADHD 
compared to placebo and other medications. The effect sizes for stimulants are some-
what higher than for non-stimulants. Adult ADHD patients cause higher annual direct 
and indirect costs than matched controls. The average medical costs are reported with 
1.262 US-Dollar in 1998 and 1.673 US-Dollar in 2001. CONCLUSIONS: Method-
ological limitations of the RCT are the short study duration and the high drop-out 
rates. Further research is needed to determine the cost-effectiveness of medical treat-
ment of adult ADHD patients.
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SWEDEN
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OBJECTIVES: To determine the prevalence of affective disorders (section F3 in 
ICD-10) in South-West region of Sweden. METHODS: This was a retrospective 
longitudinal descriptive database study of the utilization of health care of patients 
from the South-West region of Sweden (1.5 million inhabitants). All patients who were 
diagnosed with affective disorders between 2001 and 2007 in the South-West region 
of Sweden were included in the study. The patients were diagnosed in primary-, in- and 
out-patient care. RESULTS: A total of 138,194 patients were diagnosed with at least 
one type of affective disorder. This corresponded to a prevalence of 9% in the popula-
tion of South-West region in Sweden. 89 percent (123,524 patients) of the total sample 
were diagnosed with major depressive disorder (F32) followed by recurrent depressive 
disorder (F33) at 14% (19,944 patients). Bipolar affective disorder (F31) was diag-
nosed in 5% of the patients (6932) and unspeciﬁ ed mood (affective) disorder (F39) 
was diagnosed in 4% of the patients (5,431). The prevalence of the different diagnoses 
were 8 percent for depressive episode, 1 percent for recurrent depressive disorder, 0.5 
percent for bipolar affective disorder, 0.4% for unspeciﬁ ed mood (affective) disorder. 
CONCLUSIONS: Depressive episode was by far the most common of the affective 
disorders diagnosed, with a prevalence of 8 percent. a question remains whether the 
prevalence for bipolar is underestimated as this study found it to be 0.5%. The 
expected prevalence for bipolar disorder is 1 percent of the population. One plausible 
explanation could be that bipolar patients are classiﬁ ed with other codes than F31 in 
the South-West region of Sweden.
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OBJECTIVES: Despite the use of antipsychotics to treat dementia patients, the efﬁ cacy 
of the treatment is not well established. We examine factors associated with antipsy-
chotics use among community-dwelling older persons with dementia. METHODS: 
We used data from The Aging, Demographics, and Memory Study (ADAMS) to assess 
dementia severity and service use from 2002 to 2004. We used logistic regressions to 
identify factors associated with antipsychotic use; N = 307. RESULTS: Among older 
persons with dementia living in community (weighted sample = 207,544), 7.8% 
(weighted sample = 16,272) took any antipsychotic medications; 69.1% were female, 
70.7% were white, and 21.8% were African American. The average age was 85 years. 
Physical functions were measured by the number of ADL (average. 2.9) and number 
of IADL (mean 3.6). The most frequent primary diagnoses were Alzheimer’s disease 
(74.3%), vascular dementia (16.0%) and other dementia (9.8%).The most frequently 
prescribed antipsychotics were: risperidone (58.0%), quetiapine (15.4%), and halo-
peridol (7.7%). Of those taking an antipsychotic, 86.0% were diagnosed with 
Alzheimer’s dementia. We used the Neuropsychiatry Inventory (NPI) for behavior 
problems (delusions, hallucinations, agitation/aggression, depression, apathy, elation, 
anxiety, disinhibition, irritability/lability, and aberrant motor behavior). We evaluated 
severity of dementia using the Clinical Dementia Rating Scale (CDR).Community-
dwelling older persons with dementia are signiﬁ cantly more likely to receive antipsy-
chotics if they were agitated (OR = 3.4, P < 0.05), had disinhibition (OR = 4.6, P < 
0.05), or had greater dementia severity (OR = 1.9, P < 0.01). Also, Medicaid recipients 
were signiﬁ cantly more likely to receive antipsychotic medications (OR = 5.4, P < 
0.01). Participants were signiﬁ cantly less likely to be medicated with antipsychotics if 
they had vascular dementia (OR = 0.09, P < 0.05) or the caregivers were clinically 
depressed (OR = 0.2, P < 0.05). CONCLUSIONS: Community-dwelling older persons 
with dementia are more likely to receive antipsychotics if caregivers report behavior 
problems, the dementia is more advanced, and the patient has Medicaid coverage. 
Persons with vascular dementia are less likely to be treated with antipsychotics.
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OBJECTIVES: Treatment discontinuation in psychiatric care is a major cause for the 
deterioration of mental health problems. This study assessed reasons for treatment 
discontinuation of patients suffering from schizophrenia or depression in a local 
mental health care system in Germany. METHODS: A retrospective survey was per-
formed to assess how coordination of care through mental health care providers in 
the Rhein-Kreis-Neuss region (Germany) is organized. Within this survey reasons for 
treatment discontinuation were explored from the perspective of providers and 
patients. 88 providers of care (60 institutions) and 30 patients diagnosed with schizo-
phrenia and 17 patients diagnosed with major depression were interviewed using in-
depth face-to-face interviews. Additionally providers were qualitatively interviewed 
on strategies to prevent discontinuations. RESULTS: Providers were asked to rank 
pre-speciﬁ ed reasons for treatment discontinuation according to their occurrence 
(often, occasionally, seldom, never). 38.8 % ranked non-adherence to medication as 
often, 38.1 % waiting times for next treatment. 25.6 % identiﬁ ed problems in the 
patient’s social environment as being often a reason for treatment discontinuation, 
23.7 % mentioned revolving doors effects, 19.3 % resistance to therapy and 12.3 % 
lack of communication between providers. Patients diagnosed with schizophrenia 
(mean age 45 years; mean duration of illness 16 years) and depression (mean age 45 
years; mean duration of illness 13 years) indicated that they consider discontinuation 
or actually discontinue treatment when there is a lack of social integration or when 
there is no reaction of providers to articulated problems with treatments. In response 
to an open question on suggestions for improvement, providers recommended better 
cross-sectoral coordination, earlier start of treatment and early return to normal daily 
living as appropriate measures. CONCLUSIONS: From the subjective perspective of 
providers and patients a variety of causes seem to inﬂ uence treatment discontinuation. 
More research into speciﬁ c interventions to improve treatment adherence is needed.
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OBJECTIVES: To assess if patients suffering from schizophrenia or depression are 
affected by waiting times for the next treatment in a mental health care system in 
Germany. METHODS: Aa retrospective survey was performed to assess coordination 
of care through providers engaged in the care for patients with schizophrenia or major 
depression in the Rhein-Kreis-Neuss region (Germany). One parameter for evaluating 
quality of coordination is the occurrence of waiting times, emerging when patients are 
